Henry Schein, Inc. announced a strategic investment by funds affiliated with KKR, a global investment firm, totaling $250 million in the company's common stock. This investment makes KKR the largest non-index fund shareholder with a 12% position, with an option to increase its stake to 14.9%.
In connection with the investment, Max Lin, a Partner at KKR, and William K. “Dan” Daniel, an Executive Advisor to KKR and former Executive Vice President at Danaher Corporation, will join Henry Schein’s Board of Directors as independent directors. Robert J. “Bob” Hombach was also appointed as an independent director, bringing extensive financial and strategic healthcare experience.
Henry Schein also announced preliminary unaudited fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19. The company provided preliminary 2025 financial guidance, expecting full-year non-GAAP EPS to grow in the low to mid-single digits.
The Board of Directors authorized an additional $500 million to the company’s stock repurchase program, with $250 million to be executed through accelerated share repurchases. This move aims to enhance shareholder value and demonstrates confidence in the company's future.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.